Inhaled nitric oxide for the adjunctive therapy of severe malaria: Protocol for a randomized controlled trial

Trials

Volumn 12, Issue , 2011, Pages

  Hawkes, Michael ^a,b   Opoka, Robert O ^c   Namasopo, Sophie ^d   Miller, Christopher ^e   Thorpe, Kevin E ^f,g   Lavery, James V ^f,h   Conroy, Andrea L ^a   Liles, W Conrad ^a,i,j,k   John, Chandy C ^l   Kain, Kevin C ^a,i,j,k  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c MULAGO HOSPITAL   (Uganda)

^d Jinja Regional Referral Hospital   (Uganda)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g ST MICHAEL'S HOSPITAL   (Canada)

^h ST MICHAEL'S HOSPITAL   (Canada)

ⁱ McLaughlin Rotman Centre for Global Health   (Canada)

^j McLaughlin Centre for Molecular Medicine   (Canada)

^k TORONTO GENERAL HOSPITAL   (Canada)

^l UNIVERSITY OF MINNESOTA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; ARGININE; BIOLOGICAL MARKER; NITRIC OXIDE; NITRIC OXIDE DONOR; PLACEBO; VASODILATOR AGENT;

ADJUVANT THERAPY; ARTICLE; CHILD; CLINICAL PROTOCOL; COMPUTER SIMULATION; CONTROLLED STUDY; CONVALESCENCE; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIUM; ERYTHROCYTE; FOOD AND DRUG ADMINISTRATION; GAS; HUMAN; MAJOR CLINICAL STUDY; MALARIA; MORTALITY; OUTCOME ASSESSMENT; PARASITE; PATHOGENESIS; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; QUALITY CONTROL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY FAILURE; SAMPLE SIZE; STATISTICAL MODEL; TREATMENT OUTCOME; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; HOSPITALIZATION; INFANT; INHALATIONAL DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; PLACEBO EFFECT; PRESCHOOL CHILD; TIME; UGANDA; VASCULAR ENDOTHELIUM;

ADMINISTRATION, INHALATION; ANGIOPOIETIN-2; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; ENDOTHELIUM, VASCULAR; HUMANS; INFANT; LINEAR MODELS; MALARIA; NITRIC OXIDE; PLACEBO EFFECT; PROSPECTIVE STUDIES; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; UGANDA; VASODILATOR AGENTS;

EID: 79960133903     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-12-176     Document Type: Article

References (77)

1. WHO World malaria report 2008. 2008, WHO, Geneva, Switzerland, WHO.
2. John CC, Bangirana P, Byarugaba J, Opoka RO, Idro R, Jurek AM, Wu B, Boivin MJ. Cerebral malaria in children is associated with long-term cognitive impairment. Pediatrics 2008, 122:e92-99. 10.1542/peds.2007-3709, 2607241, 18541616.
3. Newton CR, Krishna S. Severe falciparum malaria in children: current understanding of pathophysiology and supportive treatment. Pharmacol Ther 1998, 79:1-53. 10.1016/S0163-7258(98)00008-4, 9719344.
4. Dondorp A, Nosten F, Stepniewska K, Day N, White N. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 2005, 366:717-725.
5. Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, Chhaganlal KD, Bojang K, Olaosebikan R, Anunobi N, Maitland K, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 376:1647-1657.
6. John CC, Kutamba E, Mugarura K, Opoka RO. Adjunctive therapy for cerebral malaria and other severe forms of Plasmodium falciparum malaria. Expert Rev Anti Infect Ther 8:997-1008.
7. Korhonen R, Lahti A, Kankaanranta H, Moilanen E. Nitric oxide production and signaling in inflammation. Curr Drug Targets Inflamm Allergy 2005, 4:471-479. 10.2174/1568010054526359, 16101524.
8. Bogdan C. Nitric oxide and the immune response. Nat Immunol 2001, 2:907-916.
9. Matsushita K, Morrell CN, Cambien B, Yang SX, Yamakuchi M, Bao C, Hara MR, Quick RA, Cao W, O'Rourke B, et al. Nitric oxide regulates exocytosis by S-nitrosylation of N-ethylmaleimide-sensitive factor. Cell 2003, 115:139-150. 10.1016/S0092-8674(03)00803-1, 2846406, 14567912.
10. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987, 327:524-526. 10.1038/327524a0, 3495737.
11. Gramaglia I, Sobolewski P, Meays D, Contreras R, Nolan JP, Frangos JA, Intaglietta M, van der Heyde HC. Low nitric oxide bioavailability contributes to the genesis of experimental cerebral malaria. Nat Med 2006, 12:1417-1422.
12. Anstey NM, Weinberg JB, Hassanali MY, Mwaikambo ED, Manyenga D, Misukonis MA, Arnelle DR, Hollis D, McDonald MI, Granger DL. Nitric oxide in Tanzanian children with malaria: inverse relationship between malaria severity and nitric oxide production/nitric oxide synthase type 2 expression. J Exp Med 1996, 184:557-567. 10.1084/jem.184.2.557, 2192721, 8760809.
13. Lopansri BK, Anstey NM, Weinberg JB, Stoddard GJ, Hobbs MR, Levesque MC, Mwaikambo ED, Granger DL. Low plasma arginine concentrations in children with cerebral malaria and decreased nitric oxide production. Lancet 2003, 361:676-678. 10.1016/S0140-6736(03)12564-0, 12606182.
14. Yeo TW, Lampah DA, Tjitra E, Gitawati R, Darcy CJ, Jones C, Kenangalem E, McNeil YR, Granger DL, Lopansri BK, et al. Increased asymmetric dimethylarginine in severe falciparum malaria: association with impaired nitric oxide bioavailability and fatal outcome. PLoS Pathog 6:e1000868.
15. Kun JF, Mordmuller B, Perkins DJ, May J, Mercereau-Puijalon O, Alpers M, Weinberg JB, Kremsner PG. Nitric oxide synthase 2(Lambarene) (G-954C), increased nitric oxide production, and protection against malaria. J Infect Dis 2001, 184:330-336. 10.1086/322037, 11443559.
16. Dhangadamajhi G, Mohapatra BN, Kar SK, Ranjit MR. The CCTTT pentanucleotide microsatellite in iNOS promoter influences the clinical outcome in P. falciparum infection. Parasitol Res 2009, 104:1315-1320. 10.1007/s00436-009-1329-9, 19153766.
17. Boutlis CS, Hobbs MR, Marsh RL, Misukonis MA, Tkachuk AN, Lagog M, Booth J, Granger DL, Bockarie MJ, Mgone CS, et al. Inducible nitric oxide synthase (NOS2) promoter CCTTT repeat polymorphism: relationship to in vivo nitric oxide production/NOS activity in an asymptomatic malaria-endemic population. Am J Trop Med Hyg 2003, 69:569-573.
18. Ohashi J, Naka I, Patarapotikul J, Hananantachai H, Looareesuwan S, Tokunaga K. Significant association of longer forms of CCTTT Microsatellite repeat in the inducible nitric oxide synthase promoter with severe malaria in Thailand. J Infect Dis 2002, 186:578-581. 10.1086/341779, 12195390.
19. Kun JF, Mordmuller B, Lell B, Lehman LG, Luckner D, Kremsner PG. Polymorphism in promoter region of inducible nitric oxide synthase gene and protection against malaria. Lancet 1998, 351:265-266. 10.1016/S0140-6736(05)78273-8, 9457101.
20. Sobolewski P, Gramaglia I, Frangos J, Intaglietta M, van der Heyde HC. Nitric oxide bioavailability in malaria. Trends Parasitol 2005, 21:415-422. 10.1016/j.pt.2005.07.002, 16039159.
21. Day NP, Phu NH, Mai NT, Chau TT, Loc PP, Chuong LV, Sinh DX, Holloway P, Hien TT, White NJ. The pathophysiologic and prognostic significance of acidosis in severe adult malaria. Crit Care Med 2000, 28:1833-1840. 10.1097/00003246-200006000-00025, 10890629.
22. MacPherson GG, Warrell MJ, White NJ, Looareesuwan S, Warrell DA. Human cerebral malaria. A quantitative ultrastructural analysis of parasitized erythrocyte sequestration. Am J Pathol 1985, 119:385-401. 1888001, 3893148.
23. Turner GD, Morrison H, Jones M, Davis TM, Looareesuwan S, Buley ID, Gatter KC, Newbold CI, Pukritayakamee S, Nagachinta B, et al. An immunohistochemical study of the pathology of fatal malaria. Evidence for widespread endothelial activation and a potential role for intercellular adhesion molecule-1 in cerebral sequestration. Am J Pathol 1994, 145:1057-1069. 1887431, 7526692.
24. De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA, Shin WS, Liao JK. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995, 96:60-68. 10.1172/JCI118074, 185173, 7542286.
25. Jakobsen PH, Morris-Jones S, Ronn A, Hviid L, Theander TG, Elhassan IM, Bygbjerg IC, Greenwood BM. Increased plasma concentrations of sICAM-1, sVCAM-1 and sELAM-1 in patients with Plasmodium falciparum or P. vivax malaria and association with disease severity. Immunology 1994, 83:665-669. 1415057, 7533138.
26. de Mast Q, Groot E, Lenting PJ, de Groot PG, McCall M, Sauerwein RW, Fijnheer R, van der Ven A. Thrombocytopenia and release of activated von Willebrand Factor during early Plasmodium falciparum malaria. J Infect Dis 2007, 196:622-628. 10.1086/519844, 17624850.
27. Hollestelle MJ, Donkor C, Mantey EA, Chakravorty SJ, Craig A, Akoto AO, O'Donnell J, van Mourik JA, Bunn J. von Willebrand factor propeptide in malaria: evidence of acute endothelial cell activation. Br J Haematol 2006, 133:562-569. 10.1111/j.1365-2141.2006.06067.x, 16681646.
28. Yeo TW, Lampah DA, Gitawati R, Tjitra E, Kenangalem E, Piera K, Price RN, Duffull SB, Celermajer DS, Anstey NM. Angiopoietin-2 is associated with decreased endothelial nitric oxide and poor clinical outcome in severe falciparum malaria. Proc Natl Acad Sci USA 2008, 105:17097-17102. 10.1073/pnas.0805782105, 2575222, 18957536.
29. Lovegrove FE, Tangpukdee N, Opoka RO, Lafferty EI, Rajwans N, Hawkes M, Krudsood S, Looareesuwan S, John CC, Liles WC, Kain KC. Serum angiopoietin-1 and -2 levels discriminate cerebral malaria from uncomplicated malaria and predict clinical outcome in African children. PLoS One 2009, 4:e4912. 10.1371/journal.pone.0004912, 2657207, 19300530.
30. Bridges DJ, Bunn J, van Mourik JA, Grau G, Preston RJ, Molyneux M, Combes V, O'Donnell JS, de Laat B, Craig A. Rapid activation of endothelial cells enables Plasmodium falciparum adhesion to platelet-decorated von Willebrand factor strings. Blood 2010, 115:1472-1474. 10.1182/blood-2009-07-235150, 2840836, 19897581.
31. Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S, Thurston G, Gale NW, Witzenrath M, Rosseau S, Suttorp N, et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 2006, 12:235-239. 10.1038/nm1351, 16462802.
32. Parikh SM, Mammoto T, Schultz A, Yuan HT, Christiani D, Karumanchi SA, Sukhatme VP. Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med 2006, 3:e46. 10.1371/journal.pmed.0030046, 1334221, 16417407.
33. Saharinen P, Eklund L, Miettinen J, Wirkkala R, Anisimov A, Winderlich M, Nottebaum A, Vestweber D, Deutsch U, Koh GY, et al. Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts. Nat Cell Biol 2008, 10:527-537. 10.1038/ncb1715, 18425119.
34. Thurston G, Suri C, Smith K, McClain J, Sato TN, Yancopoulos GD, McDonald DM. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 1999, 286:2511-2514. 10.1126/science.286.5449.2511, 10617467.
35. Fukuhara S, Sako K, Minami T, Noda K, Kim HZ, Kodama T, Shibuya M, Takakura N, Koh GY, Mochizuki N. Differential function of Tie2 at cell-cell contacts and cell-substratum contacts regulated by angiopoietin-1. Nat Cell Biol 2008, 10:513-526. 10.1038/ncb1714, 18425120.
36. Yeo TW, Lampah DA, Gitawati R, Tjitra E, Kenangalem E, McNeil YR, Darcy CJ, Granger DL, Weinberg JB, Lopansri BK, et al. Impaired nitric oxide bioavailability and L-arginine reversible endothelial dysfunction in adults with falciparum malaria. J Exp Med 2007, 204:2693-2704. 10.1084/jem.20070819, 2118490, 17954570.
37. Finer NN, Barrington KJ. Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database Syst Rev 2006, CD000399.
38. Adhikari NK, Burns KE, Friedrich JO, Granton JT, Cook DJ, Meade MO. Effect of nitric oxide on oxygenation and mortality in acute lung injury: systematic review and meta-analysis. BMJ 2007, 334:779. 10.1136/bmj.39139.716794.55, 1852043, 17383982.
39. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. Bmj 340:c332.
40. WHO Malaria rapid diagnostic test performance: results of WHO product testing of malaria RDTs: round 1. 2008, Geneva, Switzerland: WHO, WHO.
41. WHO Management of severe malnutrition: a manual for physicians and other senior health workers. 1999, Geneva, Switzerland: WHO, WHO.
42. Idro R, Aloyo J, Mayende L, Bitarakwate E, John CC, Kivumbi GW. Severe malaria in children in areas with low, moderate and high transmission intensity in Uganda. Trop Med Int Health 2006, 11:115-124. 10.1111/j.1365-3156.2005.01518.x, 16398762.
43. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. The Neonatal Inhaled Nitric Oxide Study Group. N Engl J Med 1997, 336:597-604.
44. Davidson D, Barefield ES, Kattwinkel J, Dudell G, Damask M, Straube R, Rhines J, Chang CT. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multicenter study. The I-NO/PPHN Study Group. Pediatrics 1998, 101:325-334. 10.1542/peds.101.3.325, 9480993.
45. Head CA, Swerdlow P, McDade WA, Joshi RM, Ikuta T, Cooper ML, Eckman JR. Beneficial effects of nitric oxide breathing in adult patients with sickle cell crisis. Am J Hematol 85:800-802.
46. Weiner DL, Hibberd PL, Betit P, Cooper AB, Botelho CA, Brugnara C. Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease. Jama 2003, 289:1136-1142. 10.1001/jama.289.9.1136, 12622584.
47. Long R, Jones R, Talbot J, Mayers I, Barrie J, Hoskinson M, Light B. Inhaled nitric oxide treatment of patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother 2005, 49:1209-1212. 10.1128/AAC.49.3.1209-1212.2005, 549277, 15728930.
48. Tran TH, Day NP, Nguyen HP, Nguyen TH, Pham PL, Dinh XS, Ly VC, Ha V, Waller D, Peto TE, White NJ. A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria. N Engl J Med 1996, 335:76-83. 10.1056/NEJM199607113350202, 8649493.
49. van Hensbroek MB, Onyiorah E, Jaffar S, Schneider G, Palmer A, Frenkel J, Enwere G, Forck S, Nusmeijer A, Bennett S, et al. A trial of artemether or quinine in children with cerebral malaria. N Engl J Med 1996, 335:69-75. 10.1056/NEJM199607113350201, 8649492.
50. Troncy E, Collet JP, Shapiro S, Guimond JG, Blair L, Ducruet T, Francoeur M, Charbonneau M, Blaise G. Inhaled nitric oxide in acute respiratory distress syndrome: a pilot randomized controlled study. Am J Respir Crit Care Med 1998, 157:1483-1488.
51. Griffiths MJ, Evans TW. Inhaled nitric oxide therapy in adults. N Engl J Med 2005, 353:2683-2695. 10.1056/NEJMra051884, 16371634.
52. Leavey JF, Dubin RL, Singh N, Kaminsky DA. Silo-Filler's disease, the acute respiratory distress syndrome, and oxides of nitrogen. Ann Intern Med 2004, 141:410-411.
53. Elsayed NM. Toxicity of nitrogen dioxide: an introduction. Toxicology 1994, 89:161-174. 10.1016/0300-483X(94)90096-5, 8023327.
54. Svolba G, Bauer P. Statistical quality control in clinical trials. Control Clin Trials 1999, 20:519-530. 10.1016/S0197-2456(99)00029-X, 10588293.
55. NIAID Division of Microbiology and Infectious Diseases Pediatric Toxicity Tables (revised 11.21.07). NIAID.
56. WHO WHO standard definitions for adverse event WHO., http://www.who.int/vaccines-documents/DocsPDF05/815.pdf.
57. Wendler DS. Assent in paediatric research: theoretical and practical considerations. J Med Ethics 2006, 32:229-234. 10.1136/jme.2004.011114, 2588342, 16574878.
58. Newman PA. Towards a science of community engagement. Lancet 2006, 367:302.
59. Tindana PO, Singh JA, Tracy CS, Upshur RE, Daar AS, Singer PA, Frohlich J, Lavery JV. Grand challenges in global health: community engagement in research in developing countries. PLoS Med 2007, 4:e273. 10.1371/journal.pmed.0040273, 1989740, 17850178.
60. Lavery JV, Tinadana PO, Scott TW, Harrington LC, Ramsey JM, Ytuarte-Nunez C, James AA. Towards a framework for community engagement in global health research. Trends Parasitol 26:279-283.
61. Boivin MJ, Bangirana P, Byarugaba J, Opoka RO, Idro R, Jurek AM, John CC. Cognitive impairment after cerebral malaria in children: a prospective study. Pediatrics 2007, 119:e360-366. 10.1542/peds.2006-2027, 2743741, 17224457.
62. Hrobjartsson A, Forfang E, Haahr MT, Als-Nielsen B, Brorson S. Blinded trials taken to the test: an analysis of randomized clinical trials that report tests for the success of blinding. Int J Epidemiol 2007, 36:654-663. 10.1093/ije/dym020, 17440024.
63. Sokol J, Jacobs SE, Bohn D. Inhaled nitric oxide for acute hypoxemic respiratory failure in children and adults. Cochrane Database Syst Rev 2003, CD002787.
64. Hansen TW. Inhaled nitric oxide and the societal perspective. Pediatrics 2004, 113:1849-1851; author reply 1849-1851. 10.1542/peds.113.6.1849, 15173527.
65. Angus DC, Clermont G, Watson RS, Linde-Zwirble WT, Clark RH, Roberts MS. Cost-effectiveness of inhaled nitric oxide in the treatment of neonatal respiratory failure in the United States. Pediatrics 2003, 112:1351-1360. 10.1542/peds.112.6.1351, 14654609.
66. Pierce CM, Peters MJ, Cohen G, Goldman AP, Petros AJ. Cost of nitric oxide is exorbitant. Bmj 2002, 325:336. 10.1136/bmj.325.7359.336, 1123840, 12169517.
67. Maitland K, Nadel S, Pollard AJ, Williams TN, Newton CR, Levin M. Management of severe malaria in children: proposed guidelines for the United Kingdom. Bmj 2005, 331:337-343. 10.1136/bmj.331.7512.337, 1183138, 16081449.
68. Akech S, Gwer S, Idro R, Fegan G, Eziefula AC, Newton CR, Levin M, Maitland K. Volume expansion with albumin compared to gelofusine in children with severe malaria: results of a controlled trial. PLoS Clin Trials 2006, 1:e21. 10.1371/journal.pctr.0010021, 1569382, 16998584.
69. Enwere G. A review of the quality of randomized clinical trials of adjunctive therapy for the treatment of cerebral malaria. Trop Med Int Health 2005, 10:1171-1175. 10.1111/j.1365-3156.2005.01505.x, 16262742.
70. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982, 38:963-974. 10.2307/2529876, 7168798.
71. Hawkes M, Kain KC. Advances in malaria diagnosis. Expert Rev Anti Infect Ther 2007, 5:485-495. 10.1586/14787210.5.3.485, 17547512.
72. Henschel AD, Rothenberger LG, Boos J. Randomized clinical trials in children--ethical and methodological issues. Curr Pharm Des 16:2407-2415.
73. Molyneux CS, Peshu N, Marsh K. Trust and informed consent: insights from community members on the Kenyan coast. Soc Sci Med 2005, 61:1463-1473. 10.1016/j.socscimed.2004.11.073, 16005781.
74. Lynoe N, Hyder Z, Chowdhury M, Ekstrom L. Obtaining informed consent in Bangladesh. N Engl J Med 2001, 344:460-461.
75. Kyu HH, Fernandez E. Artemisinin derivatives versus quinine for cerebral malaria in African children: a systematic review. Bull World Health Organ 2009, 87:896-904. 10.2471/BLT.08.060327, 2789363, 20454480.
76. Conroy AL, Lafferty EI, Lovegrove FE, Krudsood S, Tangpukdee N, Liles WC, Kain KC. Whole blood angiopoietin-1 and -2 levels discriminate cerebral and severe (non-cerebral) malaria from uncomplicated malaria. Malar J 2009, 8:295. 10.1186/1475-2875-8-295, 2806378, 20003529.
77. Conroy AL, Phiri H, Hawkes M, Glover S, Mallewa M, Seydel KB, Taylor TE, Molyneux ME, Kain KC. Endothelium-based biomarkers are associated with cerebral malaria in malawian children: a retrospective case-control study. PLoS One 5:e15291.